Dr. Kevin Scanlon's has a background that includes: academic medicine, senior management in the pharmaceutical industry, CEO of four start-up biotechnology companies and an angel investor. He is the Chairman Emeritus of Pasadena Angels Investment Group. Dr. Scanlon has worked with entrepreneurs, the investment community and international governments in Ireland, China and New Zealand to create an innovative culture around the intellectual property from their academic institutions. He is currently CEO of the stem cell technology company for skin care, Makucell. Makucell is one of four early stage biotechnology companies that he has helped spinout from academic institutions. As a Pharmaceutical Industry-Vice President at Berlex-Schering AG (Berlin, Germany), he was responsible for the company's international genomic and cancer research program in the US, Europe and Asia. Dr. Scanlon was a Leukemia Society Scholar, awarded the Paul Martini Medical Research Prize in Germany, a participant at 400th Anniversary of Uppsala University, Sweden, the President of the International Society of Cell and Gene Therapy, Co-Founder of the Nature journal "Cancer Gene Therapy", co-authored over 135 original scientific articles, edited nine medical books, a lead investigator on government grants and has seven issued US Patents.
Dr. Kevin Scanlon
We Are Hiring! Looking for a Post-Doc to work on my @hrbireland EIA project. Enthustiastic, focused PD needed. Experience in CRISPR and functional assessment of mutations a must. @nicb_dcu @DCUBiodesign @DcuBiotech @DCUFSH Job detaile here: https://www.findapostdoc.com/search/job-details.aspx?jobcode=9451
New article covering the recent success of the School's 12th Annual Research Day which went online for the first time.
Read about the research currently being undertaken in the School, in addition to the generous donation made by the @BRS_DCU